Professor Ammar Al-Chalabi MB, ChB, PhD
Professor of Neurology and Complex Disease Genetics
Research interests
- Neuroscience
Contact details
Biography
My research focuses on amyotrophic lateral sclerosis, also known as ALS or motor neuron disease. My research team works on finding the causes of ALS, and what might influence the way the disease manifests and progresses, particularly where this involves genes, environmental exposures, or changes in thinking and coping. I lead the Motor Neuron Disease reseach theme at the NIHR Maudsley Biomedical Research Centre.
I have also held fellowships and exchange positions abroad at Massachusetts General Hospital, Harvard University and Cold Spring Harbor Laboratory. I set up the MSc in Clinical Neuroscience at King's College London, which is our clinical research trainee programme.
I have authored more than 250 peer-reviewed papers and hold extensive external grant funding, including three current and six recently completed programme grants, as well as funding from Medical Research Council, Horizon 2020, and National Institute for Health and Care Research.
Please see my Research Staff Profile for more detail
Key publications
- Van Rheenen et al., 2016. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis Letter
- Al-Chalabi et al., 2014. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study Volume 13, Issue 11
- Fang et al., 2018. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study Volume 17, Issue 5
Key collaborators
- Professor Leonard van den Berg, University Medical Center Utrecht
- Professor Orla Hardiman, Trinity College Dublin
- Professor Christopher McDermott, University of Sheffield
- Professor Chris Shaw, King's College London
Research
The RHAPSODY Study
Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric disorders (RHAPSODY)
Project status: Ongoing
News
Over £1.4 million awarded to King's researchers to accelerate MND treatment development
Three projects led by researchers at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) have received MND Translational Accelerator awards...
King's Motor Neurone Disease Care and Research Centre Hosts Delegation from Perron Institute and Western Australian Government
The esteemed guests included Steve Arnott, CEO of Perron Institute, and John Langoulant, Agent General for Western Australia.
Professor Ammar Al-Chalabi elected as Fellow of the Academy of Medical Sciences
Professor Ammar Al-Chalabi has been elected as a Fellow of the prestigious Academy for his remarkable contributions to advancing biomedical and health...
King's College London and LifeArc team up to accelerate MND treatment development
LifeArc has pledged £1.5 million to fund a new two-year collaborative partnership with King’s College London.
Three King's academics elected as Fellows of the Academy of Medical Sciences
Professors Ammar Al-Chalabi, Maddy Parsons and Jane Sandall have been elected as Fellows of the prestigious Academy in recognition of their industry-leading...
New research institute to accelerate the search for a cure for MND
A new research institute to accelerate the search for a cure for motor neuron disease (MND, also known as ALS), launches today in London.
New programme to move potential MND drugs into clinical trials faster
A ground-breaking experimental medicine programme that will enable researchers to more rapidly screen potential drugs in people with motor neuron disease...
PrecisionLife completes data access agreement with King's College London to enable new precision neuroscience treatments and diagnostics in MND/ALS
The techbio company, PrecisionLife, announced that it has agreed a data access and licensing agreement with King’s College London to enable it to generate and...
Secretary of State for Health and Social Care visits King's College London
Following a meeting of sector leaders, the Rt Hon Stephen Barclay MP, Secretary of State for Health and Social Care, met with scientists from King’s College...
Treatment for Motor Neurone Disease shows promise
A trial investigating a new treatment for amyotrophic lateral sclerosis (ALS) has shared promising results.
Research
The RHAPSODY Study
Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric disorders (RHAPSODY)
Project status: Ongoing
News
Over £1.4 million awarded to King's researchers to accelerate MND treatment development
Three projects led by researchers at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) have received MND Translational Accelerator awards...
King's Motor Neurone Disease Care and Research Centre Hosts Delegation from Perron Institute and Western Australian Government
The esteemed guests included Steve Arnott, CEO of Perron Institute, and John Langoulant, Agent General for Western Australia.
Professor Ammar Al-Chalabi elected as Fellow of the Academy of Medical Sciences
Professor Ammar Al-Chalabi has been elected as a Fellow of the prestigious Academy for his remarkable contributions to advancing biomedical and health...
King's College London and LifeArc team up to accelerate MND treatment development
LifeArc has pledged £1.5 million to fund a new two-year collaborative partnership with King’s College London.
Three King's academics elected as Fellows of the Academy of Medical Sciences
Professors Ammar Al-Chalabi, Maddy Parsons and Jane Sandall have been elected as Fellows of the prestigious Academy in recognition of their industry-leading...
New research institute to accelerate the search for a cure for MND
A new research institute to accelerate the search for a cure for motor neuron disease (MND, also known as ALS), launches today in London.
New programme to move potential MND drugs into clinical trials faster
A ground-breaking experimental medicine programme that will enable researchers to more rapidly screen potential drugs in people with motor neuron disease...
PrecisionLife completes data access agreement with King's College London to enable new precision neuroscience treatments and diagnostics in MND/ALS
The techbio company, PrecisionLife, announced that it has agreed a data access and licensing agreement with King’s College London to enable it to generate and...
Secretary of State for Health and Social Care visits King's College London
Following a meeting of sector leaders, the Rt Hon Stephen Barclay MP, Secretary of State for Health and Social Care, met with scientists from King’s College...
Treatment for Motor Neurone Disease shows promise
A trial investigating a new treatment for amyotrophic lateral sclerosis (ALS) has shared promising results.